Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2022 | 423 | 3.450 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2024 | 65 | 1.510 |
Why?
|
| Hematologic Diseases | 3 | 2017 | 77 | 1.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2019 | 939 | 0.850 |
Why?
|
| Immunotherapy | 2 | 2020 | 761 | 0.840 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2024 | 224 | 0.720 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 36 | 0.710 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 96 | 0.660 |
Why?
|
| Child | 18 | 2025 | 7355 | 0.600 |
Why?
|
| Ploidies | 1 | 2019 | 39 | 0.590 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 68 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 2544 | 0.480 |
Why?
|
| Adolescent | 19 | 2025 | 9606 | 0.470 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 260 | 0.470 |
Why?
|
| Immune System Diseases | 1 | 2015 | 25 | 0.450 |
Why?
|
| Burkitt Lymphoma | 1 | 2014 | 34 | 0.410 |
Why?
|
| Young Adult | 17 | 2025 | 6930 | 0.400 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 109 | 0.390 |
Why?
|
| Oxides | 2 | 2010 | 42 | 0.390 |
Why?
|
| Arsenicals | 2 | 2010 | 49 | 0.390 |
Why?
|
| Child, Preschool | 9 | 2024 | 3829 | 0.340 |
Why?
|
| Folic Acid | 1 | 2011 | 62 | 0.340 |
Why?
|
| Neoplasms | 4 | 2025 | 3169 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1448 | 0.330 |
Why?
|
| Humans | 35 | 2025 | 93501 | 0.320 |
Why?
|
| Carnitine | 2 | 2021 | 14 | 0.310 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2010 | 44 | 0.310 |
Why?
|
| Asparaginase | 2 | 2021 | 35 | 0.310 |
Why?
|
| Infant | 6 | 2024 | 3220 | 0.300 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2021 | 66 | 0.300 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 2302 | 0.300 |
Why?
|
| Communicable Diseases | 1 | 2010 | 69 | 0.290 |
Why?
|
| Injections, Spinal | 2 | 2022 | 48 | 0.290 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 204 | 0.290 |
Why?
|
| Glucocorticoids | 1 | 2010 | 362 | 0.270 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 826 | 0.270 |
Why?
|
| Polyethylene Glycols | 2 | 2021 | 373 | 0.260 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1659 | 0.260 |
Why?
|
| Remission Induction | 5 | 2019 | 738 | 0.240 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 283 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 38 | 0.210 |
Why?
|
| Male | 19 | 2024 | 44552 | 0.210 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 248 | 0.210 |
Why?
|
| Quality of Life | 2 | 2025 | 1780 | 0.200 |
Why?
|
| Female | 19 | 2024 | 48696 | 0.200 |
Why?
|
| Disease-Free Survival | 3 | 2024 | 1170 | 0.190 |
Why?
|
| Prognosis | 4 | 2020 | 3910 | 0.190 |
Why?
|
| Leukemia, B-Cell | 1 | 2022 | 22 | 0.180 |
Why?
|
| Research Design | 1 | 2025 | 616 | 0.180 |
Why?
|
| Etoposide | 2 | 2019 | 204 | 0.180 |
Why?
|
| Methotrexate | 1 | 2022 | 225 | 0.170 |
Why?
|
| Survivors | 2 | 2020 | 204 | 0.170 |
Why?
|
| Cytogenetic Analysis | 2 | 2019 | 71 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1103 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2022 | 10163 | 0.160 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 196 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2479 | 0.150 |
Why?
|
| Anthracyclines | 1 | 2019 | 31 | 0.150 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 372 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 826 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2024 | 9097 | 0.150 |
Why?
|
| Leukemia | 1 | 2021 | 301 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2010 | 2562 | 0.140 |
Why?
|
| Recurrence | 1 | 2022 | 1190 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2020 | 88 | 0.140 |
Why?
|
| Hyperbilirubinemia | 1 | 2018 | 20 | 0.140 |
Why?
|
| Adult | 12 | 2021 | 27918 | 0.130 |
Why?
|
| Risk Factors | 3 | 2020 | 5898 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 43 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2018 | 235 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 150 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2020 | 960 | 0.120 |
Why?
|
| Prevalence | 2 | 2018 | 1321 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 145 | 0.120 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 5 | 0.120 |
Why?
|
| Blood Culture | 1 | 2016 | 13 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 36 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2017 | 320 | 0.110 |
Why?
|
| Bone Marrow Examination | 1 | 2015 | 40 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 2015 | 44 | 0.110 |
Why?
|
| Imatinib Mesylate | 1 | 2015 | 127 | 0.110 |
Why?
|
| Survival Rate | 4 | 2021 | 1948 | 0.110 |
Why?
|
| Bacteremia | 1 | 2016 | 108 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 636 | 0.110 |
Why?
|
| Prednisone | 2 | 2017 | 242 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 236 | 0.100 |
Why?
|
| U937 Cells | 2 | 2010 | 31 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2016 | 563 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 350 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 302 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 537 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2016 | 342 | 0.090 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 17 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1001 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 392 | 0.090 |
Why?
|
| Pediatrics | 1 | 2017 | 385 | 0.090 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 61 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 111 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 1014 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 59 | 0.080 |
Why?
|
| Dithiothreitol | 1 | 2010 | 25 | 0.080 |
Why?
|
| Biomarkers | 2 | 2022 | 1910 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2010 | 73 | 0.080 |
Why?
|
| Tretinoin | 1 | 2010 | 129 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2010 | 335 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2022 | 110 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2010 | 210 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 175 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2010 | 674 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 829 | 0.070 |
Why?
|
| Autophagy | 1 | 2010 | 172 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2010 | 312 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 555 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1906 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 383 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 365 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2010 | 319 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 775 | 0.070 |
Why?
|
| United States | 4 | 2025 | 7619 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 889 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2010 | 1133 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 502 | 0.060 |
Why?
|
| Induction Chemotherapy | 2 | 2021 | 146 | 0.060 |
Why?
|
| Sex Factors | 1 | 2010 | 1105 | 0.060 |
Why?
|
| Incidence | 2 | 2024 | 1701 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3828 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1713 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2755 | 0.050 |
Why?
|
| Self Report | 1 | 2025 | 328 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 1415 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 876 | 0.050 |
Why?
|
| Mucin-4 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 4559 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2012 | 0.050 |
Why?
|
| Base Sequence | 2 | 2016 | 2220 | 0.050 |
Why?
|
| Seizures | 1 | 2024 | 311 | 0.040 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 32 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 841 | 0.040 |
Why?
|
| Sepsis | 1 | 2024 | 388 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 756 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 304 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1524 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2018 | 91 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 1799 | 0.030 |
Why?
|
| Vinblastine | 1 | 2017 | 85 | 0.030 |
Why?
|
| Vincristine | 1 | 2017 | 99 | 0.030 |
Why?
|
| Bleomycin | 1 | 2017 | 99 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2017 | 100 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 278 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2017 | 284 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1531 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 168 | 0.030 |
Why?
|
| Oncologists | 1 | 2016 | 38 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1161 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1723 | 0.030 |
Why?
|
| Marital Status | 1 | 2016 | 43 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 702 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 197 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 255 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 364 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 3054 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 134 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 337 | 0.020 |
Why?
|
| Liver | 1 | 2018 | 1206 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 917 | 0.020 |
Why?
|
| Genes, myc | 1 | 2012 | 37 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 50 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 83 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 2017 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 78 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 544 | 0.020 |
Why?
|
| World Health Organization | 1 | 2012 | 121 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 224 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5410 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 264 | 0.020 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2010 | 12 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1847 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1917 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 200 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 201 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 185 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 2120 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1264 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 20430 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 12263 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 28148 | 0.010 |
Why?
|